The state’s economy greatly depends on the pharmaceutical industry in New York City, which also has room to grow. The city’s thriving health economy, which is home to top-notch hospitals and pharmaceutical firms, has been growing, especially as a result of city-led projects and the development of digital health. Most of the state’s pharmaceutical companies are located in the downstate, which includes Westchester, Long Island, and New York City.
Renowned academic institutions and research centers including Columbia University, Cornell University, and Rockefeller University are located in New York. These organizations are leaders in biomedical research and frequently work on R&D projects with pharmaceutical companies.
Over 54,000 people were employed by the biotech and pharmaceutical industries in New York in 2003, paying $3.3 billion in wages and contributing $18.1 billion to the state’s economy. Every job generated within these sectors also creates another job outside of them. New York’s strategic government programs, close proximity to Wall Street and venture capital firms, and academic and research institutions all contribute to the state’s dominant position in the pharmaceutical industry. Notwithstanding, the potential for growth in this industry in New York may be hindered by the absence of reasonably priced real estate and competition from other states.
Our Top 10 Best Pharmaceutical Companies in New York:
- Zetagen Therapeutics
- Gilgamesh Pharmaceuticals
- Superior Biologics Inc
- Koneksa Health
- Revelio Labs
- Seelos Therapeutics
- Apotheco Pharmacy Group
- Clever Leaves
- Unipharm, Inc
- Medwiz Pharmacy
A Closer Look at the Top 10 Best pharmaceutical companies in New York
Zetagen Therapeutics, a well-known pharmaceutical company making major advancements in the medical field, is based in Syracuse, New York. They are a privately held, clinical-stage biopharmaceutical business committed to creating cutting-edge osteologic interventions and treatments for metastatic bone cancers.
The goal of the company’s leadership, which includes CEO Joe C. Loy, is to provide patients with metastatic bone cancers with innovative technologies. Their diverse backgrounds in finance, manufacturing, and medical device industries enable them to contribute a wealth of experience that helps the company achieve its goals.
Zetagen Therapeutics has developed several notable products, including ZetaMet™ and ZetaMAST™. ZetaMet™ is a groundbreaking molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone, and it is currently in Phase 2a clinical trials for treating metastatic breast cancer lesions on the bone. ZetaMAST™ is a proprietary hydrogel carrier intended for a single intra-tumoral injection to treat metastatic lesions in soft tissue organs.
To help advance these products, the company has gotten a lot of funding, including a recent $9.79 million USD Series B funding round. ZetaMet™ and ZetaFuse® have also received Breakthrough Device Designations from the FDA, a testament to the innovative nature of their products.
Zetagen Therapeutics has created a bioceramic bone graft material to aid in healing during surgical procedures, in addition to their cancer treatments. Their products may find use in a number of fields, such as bone fracture healing and spinal surgery. The company’s research holds promise for both stimulating bone formation and possibly preventing or eliminating tumor growth, which could be extremely helpful in situations involving post-surgical cancer treatment.
For more detailed information about their achievements and ongoing projects, you can visit their website www.zetagen.com.
New York-based Gilgamesh Pharmaceuticals is a clinical-stage biotechnology company dedicated to revolutionizing mental health treatment. They are setting the standard for mental healthcare by concentrating on long-lasting, fast-acting treatments that address the underlying causes of illnesses rather than just treating symptoms.
The strategy used by the company is creating best-in-class novel chemical entities (NCEs) with established mechanisms of action. The safety, effectiveness, and patient access of these entities are maximized. Gilgamesh Pharmaceuticals uses an AI-driven translational and discovery platform in conjunction with its extensive knowledge of medicinal chemistry to expedite the development of its cutting-edge precision psychiatric treatments.
Their pipeline includes several promising products:
- NMDAR Antagonist: An orally bioavailable, rapid-acting product with fewer dissociative effects, mainly targeting depression and other indications.
- 5-HT2AR Agonists: Both hallucinogenic and non-hallucinogenic versions, optimized for duration of effect and improved cardiac safety, also aimed at treating depression and other conditions.
- Safer Ibogaine Analogs: Focused on rapid and sustained efficacy with an improved cardiac safety profile, primarily for opioid abuse disorder and other indications.
In comparison to current treatments, these medications offer increased safety, tolerability, duration, and efficacy, marking a substantial advancement in the treatment of mental health diseases. Another noteworthy aspect of Gilgamesh Pharmaceuticals is its partnerships with top biotech innovation research universities.
Their study represents an exciting breakthrough in the field of psychedelic therapeutics, and their dedication to creating innovative treatments for mental health is part of a larger effort to solve the global mental health epidemic. Gilgamesh Pharmaceuticals wants to be at the forefront of the development of psychedelic chemicals and treatments by building a portfolio of innovative compounds that harness the therapeutic advantages of psychedelics.
For more detailed information about their achievements and ongoing projects, you can visit their website www.gilgameshpharmaceutical.com.
Superior Biologics Inc
Founded in 2012, Superior Biologics Inc. is a well-known supplier of home infusion treatment services and specialized pharmacy services, with its headquarters located in Sharon Hill, Pennsylvania. The company’s mission is to provide cutting-edge, reasonably priced in-home nursing infusion treatments and pharmaceutical services. By providing best-in-class patient outcomes and maximizing treatment outcomes, these services establish Superior Biologics as a reliable partner in the healthcare sector.
The company’s goal is to create healthier communities by fusing cutting-edge technology, devoted experts, and superior clinical care. Ensuring that every patient has the chance to reach their optimal state of health and actively engage in their care is at the heart of their mission. For patients with hemophilia, Superior Biologics provides intravenous immunoglobin (IVIG) and Factor. It also offers a variety of infusion therapy for illnesses in neurology, oncology, gastrointestinal, rheumatology, and dermatology.
Superior Biologics has operated eight licensed pharmacies, six accredited pharmacies, and five nursing agencies nationwide thanks to their remarkable growth. The District of Columbia, along with all 50 states, have granted the company permission to administer therapies. The Accreditation Commission for HealthCare (ACHC), The Joint Commission (TJC), and the Utilization Review Accreditation Commission (URAC) have accredited their pharmacies.
Furthermore, Superior Biologics made headlines lately after obtaining a sizeable funding package. First Citizens Bank’s CIT division secured $135.6 million in funding for the business in the form of a revolving credit line and a term loan. This funding is meant to be used for working capital provision, growth initiative support, shareholder dividend funding, and existing debt refinancing.
The company’s strong position in the home infusion therapy and specialty pharmacy markets, as well as its dedication to ongoing development and innovation in healthcare services, are highlighted by this financial support.
For more information about Superior Biologics Inc., you can visit their website at www.superiorbiologics.com.
Koneksa Health, a trailblazing organization in the digital health space, has its headquarters in New York City. Koneksa Health, which specializes in incorporating real-world data into clinical research, is leading the charge to use digital technology to revolutionize the way clinical trials are carried out.
Using wearables and sensors, the company’s platform focuses on the remote collection and real-time analysis of patient data. This data, which includes motor activity, gait and balance, sleep, and vital signs, helps to improve access to study evidence and recruit participants for trials. Koneksa was able to raise a substantial amount of money in 2022. Takeda Ventures led a $45 million Series C funding round, and Novartis and Merck also provided support. With this funding, they hope to develop self-service features for clinical data integration solutions and grow their digital biomarker platform.
In New York City, a hub of innovation and technology, Koneksa Health benefits from access to a vibrant ecosystem of tech talent, investors, and a supportive environment for tech startups. The city’s diverse population also provides a rich environment for clinical research, enabling Koneksa Health to test and validate their technologies across varied demographics.
The growing focus in the healthcare sector on patient-centered care and personalized medicine is a good fit for Koneksa’s work. Koneksa Health is utilizing digital tools to enhance clinical research efficiency, effectiveness, and accessibility. The ultimate goal is to expedite the creation of novel therapies and enhance patient outcomes. Their location in New York City makes it easier for them to work with top medical facilities, academic institutions, and tech firms, which promotes innovation in digital health solutions.
Revelio Labs, which was founded in early 2018 by Ben Zweig and Yedidya Gorsetman, has been absorbing and evaluating public employment records in order to create a universal HR database. This platform displays trends in job postings, employee sentiment, and layoff notices in addition to vital metrics on headcounts, inflows and outflows at different levels across companies. The platform scrapes and curates data from online resumes, job postings, and public profiles using proprietary algorithms. For particular companies, this method aids in providing answers to important questions about talent acquisition and retention.
Significantly, the business completed a $15 million Series A funding round in which notable investors including Barclays, BDMI, Techstars, Elephant Partners, Alumni Ventures, and K20 Ventures contributed. With this funding, Revelio has raised $19 million in total. The company intends to use the money to expand its corporate HR and strategy offerings.
Revelio Labs distinguishes itself by providing insights into workforce dynamics, salary changes, and corporate expense projections while standardizing and interpreting HR data in a way that is understandable and helpful for financial analysts and economists. They serve a wide range of customers, including the Federal Reserve System of the United States, large financial institutions, consulting firms, and educational institutions.
The success of Revelio Labs, especially in 2021, is indicative of the company’s efforts to make human capital data in business decision-making just as valuable as financial capital, and of the growing recognition of the significance of human insights as predictors of corporate potential.
Developing treatments for disorders of the central nervous system (CNS) and uncommon diseases has been the primary focus of Seelos Therapeutics, Inc.’s noteworthy progress in the field of clinical-stage biopharmaceuticals. The successful completion of their merger with Apricus Biosciences in 2019 is one of their noteworthy accomplishments. The goal of this merger was to progress a late-stage product pipeline that addresses CNS disorders. Following the merger, Seelos Therapeutics kept its New York, New York, headquarters and carried on with business under its original name. A diversified pipeline of late-stage clinical assets in high-unmet need areas is expected to generate value from the merger, which was a calculated step towards becoming a fully-integrated multi-platform CNS company.
Seelos Therapeutics‘ pipeline includes several late-stage therapeutic candidates with proven mechanisms of action. Some of their key projects include:
- SLS-002: This intranasal racemic ketamine is intended for patients with suicidality in post-traumatic stress disorder (PTSD) and major depressive disorder (MDD). The clinical development program for SLS-002 includes healthy volunteer studies, expected to be followed by pivotal registration studies. The therapy has shown promising efficacy in suicidality (with depression) and an unremarkable safety profile.
- SLS-006: A first-in-class, small molecule, partial dopamine agonist for Parkinson’s disease, which has successfully completed phase II studies. Seelos plans to discuss plans for pivotal registration studies with the FDA and the European Medicines Authority (EMA).
- SLS-008: An oral CRTH2 (Chemo-attractant Receptor-homologous molecule expressed on TH2 cells) that focuses on an undisclosed pediatric orphan indication.
Furthermore, Seelos possesses an extensive range of products and is strategically positioned to tackle unfulfilled requirements in various CNS disorders. By creating these therapies, they hope to provide patients with options for treatment that are currently limited to transformative solutions.
Apotheco Pharmacy Group
Apotheco Pharmacy Group is a leading company with distinctive pharmacy offerings, with a focal point on oncology, hematology, and rare illnesses. The employer’s method is primarily based on an affected-person-centric model that prioritizes personalized care and aid for sufferers with complex medical situations.
Apotheco Pharmacy Group’s area of expertise in pharmacy services consists of remedy control, infusion services, affected person training and guidance, and economic help packages. The agency’s group of specialised pharmacists and nurses works carefully with healthcare carriers to ensure that sufferers acquire the proper medicinal drugs and aid for their specific situation.
One of Apotheco Pharmacy‘s key applications is centered on oncology care. The organization’s oncology software provides comprehensive medicinal drug management, together with oral chemotherapy, injectable treatments, and infusion treatments. Apotheco Pharmacy group’s team of oncology pharmacists and nurses provides personalised care and aid to patients at some stage in their treatment adventure, helping them to manage the regularly complicated regimens related to most cancer treatments.
Clever Leaves is a multinational company that specializes in the cultivation, manufacturing, and distribution of exquisite medicinal hashish. The organization’s mission is to offer patients access to safe, powerful, and low-priced medicinal cannabis products that meet the best standards of safety and compliance.
Clever Leaves operates in numerous international locations, together with Colombia, Germany, Spain, and Portugal. The corporation’s cultivation facilities are geared up with contemporary era and know-how to ensure the very best exceptional medicinal hashish products. Clever Leaves’ products are subjected to rigorous testing and nice manage measures to make certain their protection, efficacy, and compliance with regulatory requirements.
Clever Leaves‘ consciousness on cultivation, production, and distribution of first rate medicinal hashish merchandise makes it a frontrunner in the global medicinal hashish industry. The organisation’s dedication to research and improvement, training, and advocacy ensures that sufferers have get entry to to secure, effective, and low cost medicinal cannabis products that meet their particular desires.
Unipharm, Inc. Is a main pharmaceutical organization that specializes within the improvement, production, and advertising of usual and branded prescription drugs. The company’s mission is to provide outstanding, affordable drug treatments to patients round the sector.
Unipharm, Inc. Has a various product portfolio that includes a huge range of frequent and branded prescription drugs in diverse healing regions, such as cardiovascular, vital frightened gadget, gastrointestinal, breathing, and dermatological. The business enterprise’s merchandise are synthetic in trendy facilities that adhere to the best satisfactory standards and regulatory requirements.
One in every of Unipharm, Inc.’s key programs is centered on research and development. The organisation invests heavily in studies and improvement to identify new drug candidates and boost its product pipeline. Unipharm, Inc.’s research and improvement efforts are supported through a group of skilled scientists and researchers who paintings intently with healthcare companies and patients to make certain that new products are safe, powerful, and inexpensive.
Medwiz Pharmacy is a specialised online pharmacy that provides a wide variety of prescription and over-the-counter medications to sufferers within the United States and around the world. The business enterprise’s mission is to provide cheap and convenient access to extremely good medicines while ensuring the privacy and safety of its patients’ personal and health information.
Medwiz Pharmacy’s product portfolio consists of a wide variety of medicines in various therapeutic areas, consisting of cardiovascular, central nervous system, gastrointestinal, respiratory, and dermatological. The organization’s medications are sourced from legit producers and providers and are subjected to rigorous fine-manipulating measures to ensure their safety, efficacy, and compliance with regulatory requirements.
Certainly, one of Medwiz Pharmacy‘s key programs is centered on patient aid and education. The enterprise affords instructional sources and aid to help sufferers make informed choices about their healthcare picks. Medwiz Pharmacy’s group of licensed pharmacists is available to answer questions about medications, dosages, and potential aspects of results.
In the end, the variety and dynamic nature of New York’s pharmaceutical industry is a reflection of the city’s standing as a center for innovation and excellence in biotechnology and healthcare. The dynamic and innovative atmosphere that defines the pharmaceutical industry in New York is largely attributed to these ten leading pharmaceutical companies, each of which possesses distinct advantages and areas of expertise. These businesses are at the forefront of developing medical science and enhancing patient care, from industry titans in drug development and manufacturing to up-and-coming leaders in biotech and digital health.
Their presence in New York is not just a testament to the city’s conducive business climate, but also to the rich ecosystem that includes world-class research institutions, a skilled workforce, and a supportive regulatory environment. These companies benefit from the city’s infrastructure, access to capital, and diverse talent pool, enabling them to innovate and grow.
These top New York companies are well-positioned to lead the way in developing new treatments and therapies as the pharmaceutical industry continues to change due to advancements in technology and a deeper understanding of diseases. Their work is vital to New York’s scientific and economic life, and it also makes a major contribution to the global healthcare scene. Pharmaceuticals in New York City appear to have a bright future because these elite firms are at the forefront of innovation, research, and the general improvement of human health.